Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.39 |
| ▸ | GNRHR | P30968 | 7/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207055 | 0.83 | DCTPP1 (0.56) | ADORA2AADORA1GNRHRADORA3 | |
| SCHEMBL7128653 | 0.79 | GNRHR (0.40) | GNRHR | |
| SCHEMBL5201972 | 0.78 | KCNK13 (0.42) | ADORA2AADORA1 | |
| SCHEMBL5201125 | 0.70 | TLR8 (0.43) | GNRHR | |
| SCHEMBL7883265 | 0.67 | PSEN1 (0.46) | ADORA2AADORA1 | |
| SCHEMBL5203923 | 0.67 | MAPT (0.39) | ADORA2AADORA1GNRHRBUB1PDE2A | |
| SCHEMBL5203544 | 0.67 | TLR8 (0.41) | GNRHRPDE2APDE10A | |
| SCHEMBL5207236 | 0.66 | ALDH1A1 (0.40) | GNRHRBUB1 | |
| SCHEMBL5204661 | 0.65 | GNRHR (0.41) | GNRHR | |
| SCHEMBL5202583 | 0.64 | TP53 (0.39) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210336-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US HEALTH (US) | 2007-04-25 | — | — | EP | disclosed |
| US-6894068-B2 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | MICHEJDA CHRISTOPHER J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1210336-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6369235-B1 | INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-09 | — | — | US | disclosed |
| WO-2001014343-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | SAMHD1, DUT, TYMP | ADORA2A 2283/4885ADORA1 1659/4885GNRHR 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.